Bo Liu

Bo Liu

Auto-generated profile, based on publicly available information

Bo Liu

Department of Surgical Oncology The First Affiliated Hospital of Xi'an Jiaotong University Xi'an P. R. China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2023 in Cancer Medicine
Verified
Journal Article
Open access
BLBo Liu
Bo Liu
WDWeichao Dan
Weichao Dan
YWYi Wei
Yi Wei
YZYan Zhang
Yan Zhang
CWChi Wang
Chi Wang
YGYe Gao
Ye Gao
Background: β‐asarone (β‐as), a compound extracted from Acorus calamus, has been found to have anticancer effects on a variety of human cancers. However, the potential effect of β‐as on bladder cancer (BCa) remains unknown.Methods: After exposure to β‐as, migration, invasion, and epithelial‐mesenchymal transition (EMT) of BCa were determined by wound healing, transwell, and Western blot assays. Expression of proteins involved in the EMT and ER stress were explored by Western blot assays. Nude mouse xenograft model was served as the model system in vivo.Results: The migration, invasion, and EMT of BCa were significantly inhibited after β‐as treatment. Further experiments revealed that endoplasmic reticulum (ER) stress is involved in β‐as‐mediated metastasis inhibition. In addition, β‐as significantly up‐regulated activating transcription factor 6 (ATF6), a branch of ER stress, and promoted its Golgi cleavage and nuclear localization. ATF6 silencing attenuated β‐as‐mediated metastasis and EMT inhibition in BCa cells.Conclusion: Our data suggests that β‐as inhibits migration, invasion, and EMT of BCa by activating the ATF6 branch of ER stress. Thus, β‐as represents a potential candidate for BCa treatment.

20 November 2026 in Science Advances
Verified
Journal Article
Closed access
JWJingchao Wang
Jingchao Wang
DHDaoyuan Huang
Daoyuan Huang
BLBo Liu
Bo Liu
WJWeiwei Jiang
Weiwei Jiang
FDFabin Dang
Fabin Dang
WWWenyi Wei
Wenyi Wei
RICTOR plays an essential role in regulating mechanistic target of rapamycin complex 2 (mTORC2) kinase activity, but it remains largely elusive how RICTOR is aberrantly activated in human prostate cancer (PrCa). Here, we identify RICTOR as a substrate of Cullin 3–based ubiquitin ligase adaptor SPOP, an important tumor suppressor in PrCa. SPOP deficiency or cancer-derived SPOP mutations disrupt SPOP-mediated degradation of RICTOR, thereby promoting PrCa progression. Furthermore, we identify USP8 as its upstream deubiquitinase, and inhibition of USP8 specifically suppresses RICTOR/mTORC2 activity without affecting mTORC1. As such, the USP8 inhibitor induces RICTOR degradation concomitant with marked tumor suppression in vivo. Hence, these findings reveal an SPOP-USP8-RICTOR regulatory circuit that underlies PrCa tumorigenesis and provides a rationale for targeting RICTOR via USP8 inhibition as a therapeutic strategy for patients with PrCa.